Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Oncology Nurse Advisor
oncologynurseadvisor.com > news > recurrence-score-elevated-for-breast-cancer-diagnosed-within-first-year-postpartum

Recurrence Score Elevated for Breast Cancer Diagnosed Within First Year Postpartum

11+ hour, 16+ min ago   (294+ words) Oncology Nurse Advisor HealthDay News — Postpartum breast cancer (PPBC) diagnosed within the first year postpartum has a significantly elevated 21-gene Oncotype DX Recurrence Score (RS), according to a study published online July 1 in npj Breast Cancer. Shiliang Zhang, M.D., from…...

Oncology Nurse Advisor
oncologynurseadvisor.com > news > early-breast-cancer-survival-pcr-adjuvant-chemotherapy-treatment-risk

Survival in Early Breast Cancer Without pCR Improved With Adjuvant Chemotherapy

8+ mon, 4+ day ago   (304+ words) Patients with breast cancer who did not achieve a pathologic complete response (pCR) had better survival with adjuvant chemotherapy (ACT) than with neoadjuvant chemotherapy (NACT), according to results of a study published in The Oncologist. A growing body of evidence…...

Oncology Nurse Advisor
oncologynurseadvisor.com > reports > optimized-sequencing-breast-cancer-advances-care-treatment-risk

Optimized Sequencing Advances Care for HR+/HER2+ Breast Cancer

8+ mon, 3+ week ago   (419+ words) Recent phase 3 data and real-world experiences demonstrate that patient phenotype, comorbidities, and toxicity management all influence optimal sequencing in this biologically complex disease. In the phase 3 DESTINY-Breast09 trial, trastuzumab deruxtecan (T-DXd) plus pertuzumab achieved a median progression-free survival (PFS) of…...

Oncology Nurse Advisor
oncologynurseadvisor.com > news > breast-cancer-pertuzumab-trastuzumab-maintain-long-term-safety-efficacy

Pertuzumab and Trastuzumab Maintain Long-Term Safety and Efficacy in Patients With Breast Cancer

11+ mon, 1+ week ago   (280+ words) Subcutaneous delivery of fixed-dose pertuzumab and trastuzumab (PH FDC SC) was safe and well tolerated in patients with HER2-positive early breast cancer throughout 3 years of follow-up, according to continuation-phase results from the phase 2 PHranceSCa trial (NCT03674112) recently published in Clinical Breast…...

Oncology Nurse Advisor
oncologynurseadvisor.com > news > breastfeeding-recurrence-death-breast-cancer

Breastfeeding Does Not Increase Risk of Recurrence or Death in Breast Cancer Survivors

11+ mon, 2+ week ago   (309+ words) New data suggest that breastfeeding is safe for patients with stage I-III breast cancer who have hormone receptor (HR)-positive disease or carry BRCA variants.1,2 The cumulative incidence of breast cancer events at 12 months was 1.1% among patients who breastfed and…...